3Braun wald E, Bfistow MR. Congestive heart failure :fifty years of progress.Circulation,2000; 102 (20Suppl4):IV14-23.
4Fragasso G,Perseghin G,De Cobelli F et al. Efectsof metabolic modulation by trimetazidine on leftventricular function and phosphocreatine / adeno-sine triphosphate ratio in patients with heart failure.Eur Heart J,2006; 27( 8 ): 942-948.
5Stanley WC.Chandler MP.Energy metabolism in thefailing heart: potential for therapeutic interventions[J]. Heart Failure Reviews,2002; 7:115-130.
6Lopasehuk GD,Rebeyka IM,Allard MF,et al.Metabolic modulation A means to mend a brokenheart[J]. Circulation,2002; 105 : 140-142.
8Taegtmeyer H,King LM,Jones BE. Energy substrate metabolism, myocardial ischemia, and targets for phannacotherapy. Am J Cardiol, 1998,82:54K-60K.
9Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res,2000,86: 580-588.
10Stanley WC, Lopaschuk GD, Hall JL, et al. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res, 1997,33:243-257.
